argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2016-01-25 08:41 |
argenx successfully closes transaction with US funds advised by subsidiaries of…
|
English | 79.9 KB | ||
| 2015-11-17 13:57 | English | 47.3 KB | |||
| 2015-11-17 08:23 |
argenx Reports Third Quarter 2015 Financial Results and Provides Business Update
|
English | 51.4 KB | ||
| 2015-09-23 07:17 |
arGEN-X' Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A No…
|
English | 18.0 KB | ||
| 2015-08-26 08:19 |
arGEN-X ANNOUNCES HALF-YEAR RESULTS FOR 2015
|
English | 164.9 KB | ||
| 2015-08-25 18:36 | English | 2.3 MB | |||
| 2015-08-06 07:23 |
arGEN-X to Present at Wedbush PacGrow Healthcare Conference
|
English | 10.7 KB | ||
| 2015-07-30 08:12 |
arGEN-X and University of Bern enter into license agreement to develop ARGX-110…
|
English | 27.6 KB | ||
| 2015-07-16 07:11 |
arGEN-X N.V. announces change to the Board of Directors
|
English | 17.6 KB | ||
| 2015-06-01 08:46 |
arGEN-X to present at Jefferies 2015 Global Healthcare Conference on Tuesday, 2…
|
English | 86.6 KB | ||
| 2015-05-29 07:16 |
arGEN-X presents preliminary efficacy and expanded safety data from Phase I tri…
|
English | 27.2 KB | ||
| 2015-05-21 07:12 |
arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments…
|
English | 18.2 KB | ||
| 2015-05-15 10:43 | English | 466.6 KB | |||
| 2015-05-15 08:33 |
arGEN-X Reports First Quarter 2015 Financial Results and Provides Business Upda…
|
English | 54.0 KB | ||
| 2015-05-13 19:07 |
arGEN-X announces results of Annual General Meeting 2015
|
English | 15.3 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
